{"id":"berinert","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["C1 Esterase Inhibitor (C1INH)","C1 esterase inhibitor","C1INH"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"8ea0c7fe-da9d-4218-a080-0509e09bedc6","title":"BERINERT (HUMAN C1-ESTERASE INHIBITOR) KIT [CSL BEHRING GMBH]"},"ecosystem":[],"_scrapedAt":"2026-03-28T01:43:18.230Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01520623","phase":"NA","title":"Complement and Graft-versus-host Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-04","conditions":"Allografted With Myeloablative Conditioning","enrollment":70},{"nctId":"NCT06919003","phase":"PHASE2","title":"Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-22","conditions":"Kidney Transplant","enrollment":180},{"nctId":"NCT07266805","phase":"PHASE3","title":"Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency","status":"RECRUITING","sponsor":"Pharvaris Netherlands B.V.","startDate":"2025-10-16","conditions":"Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)","enrollment":32},{"nctId":"NCT07293364","phase":"NA","title":"A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema","status":"NOT_YET_RECRUITING","sponsor":"Takeda","startDate":"2026-04-01","conditions":"Hereditary Angioedema (HAE)","enrollment":514},{"nctId":"NCT04618211","phase":"PHASE2","title":"Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"Pharvaris Netherlands B.V.","startDate":"2021-02-03","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":74},{"nctId":"NCT06361537","phase":"PHASE3","title":"Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks","status":"RECRUITING","sponsor":"Octapharma","startDate":"2024-04-30","conditions":"Acute Hereditary Angio Edema","enrollment":124},{"nctId":"NCT04705831","phase":"PHASE2","title":"Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection","status":"COMPLETED","sponsor":"IMMUNOe Research Centers","startDate":"2021-01-11","conditions":"Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19","enrollment":40},{"nctId":"NCT05047185","phase":"PHASE2","title":"Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II","status":"COMPLETED","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-04-19","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":34},{"nctId":"NCT07046806","phase":"PHASE1, PHASE2","title":"Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients","status":"RECRUITING","sponsor":"Institute for Asthma and Allergy","startDate":"2025-03-10","conditions":"Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema","enrollment":10},{"nctId":"NCT01397864","phase":"","title":"C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2011-07","conditions":"Hereditary Angioedema","enrollment":181},{"nctId":"NCT05145283","phase":"PHASE2","title":"Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-03-16","conditions":"Acute Ischemic Stroke, Acute Renal Injury","enrollment":250},{"nctId":"NCT06359782","phase":"PHASE2","title":"Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)","status":"RECRUITING","sponsor":"Haaglanden Medical Centre","startDate":"2024-11-04","conditions":"Subarachnoid Hemorrhage, Aneurysmal","enrollment":128},{"nctId":"NCT04696146","phase":"PHASE1, PHASE2","title":"Berinert (C1INH) vs Placebo for DGF/IRI","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2021-03-03","conditions":"End Stage Renal Disease, Chronic Kidney Diseases","enrollment":45},{"nctId":"NCT06690047","phase":"PHASE4","title":"Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)","status":"COMPLETED","sponsor":"Bernstein Clinical Research Center","startDate":"2018-08-14","conditions":"Hereditary Angioedema","enrollment":5},{"nctId":"NCT01034969","phase":"","title":"Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-10","conditions":"Hereditary Angioedema (HAE)","enrollment":1761},{"nctId":"NCT02251041","phase":"PHASE2","title":"Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-09","conditions":"Reperfusion Injury","enrollment":143},{"nctId":"NCT05578417","phase":"","title":"A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-06-15","conditions":"Hereditary Angioedema (HAE), Angioedema","enrollment":60},{"nctId":"NCT04444895","phase":"PHASE3","title":"A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor","status":"COMPLETED","sponsor":"Shire","startDate":"2021-02-05","conditions":"Angioedema","enrollment":73},{"nctId":"NCT06414252","phase":"","title":"Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients","status":"COMPLETED","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2023-05-15","conditions":"Hereditary Angioedema","enrollment":40},{"nctId":"NCT06408805","phase":"","title":"Autonomic Nervous System Profile in Hereditary Angioedema","status":"COMPLETED","sponsor":"Istituti Clinici Scientifici Maugeri SpA","startDate":"2023-07-12","conditions":"Hereditary Angioedema","enrollment":60},{"nctId":"NCT03697187","phase":"","title":"Patient Registry to Evaluate the Real-world Safety of Ruconest®","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2018-06-30","conditions":"Hereditary Angioedema","enrollment":152},{"nctId":"NCT04912141","phase":"PHASE2","title":"Prevention of Acute Kidney Injury in Patients With NSTEMI","status":"TERMINATED","sponsor":"Pharming Technologies B.V.","startDate":"2021-04-21","conditions":"Non-ST Elevation Myocardial Infarction (NSTEMI)","enrollment":29},{"nctId":"NCT01359969","phase":"PHASE2","title":"Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2012-01-17","conditions":"Hereditary Angioedema","enrollment":57},{"nctId":"NCT04530136","phase":"PHASE2","title":"Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2020-11-30","conditions":"Confirmed Coronavirus Disease","enrollment":38},{"nctId":"NCT06210698","phase":"","title":"Angioedema Biomarker Research Study","status":"UNKNOWN","sponsor":"Foundation For Rare Disease Research","startDate":"2024-01-15","conditions":"Angioedema, Angioedemas, Hereditary, Urticaria","enrollment":600},{"nctId":"NCT04206605","phase":"PHASE3","title":"A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-05-04","conditions":"Angioedema","enrollment":77},{"nctId":"NCT01843530","phase":"PHASE3","title":"Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2013-11","conditions":"Acute ACE-induced Angioedema","enrollment":31},{"nctId":"NCT04583007","phase":"","title":"Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults","status":"NO_LONGER_AVAILABLE","sponsor":"Shire","startDate":"","conditions":"Hereditary Angioedema (HAE), Angioedema","enrollment":""},{"nctId":"NCT04888650","phase":"","title":"Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2021-05-03","conditions":"Hereditary Angioedema","enrollment":314},{"nctId":"NCT05833620","phase":"","title":"Identification and Characterization of Genetic Variants in Hereditary Angioedema","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2023-05","conditions":"Hereditary Angioedema With C1 Esterase Inhibitor Deficiency","enrollment":200},{"nctId":"NCT04030598","phase":"PHASE2","title":"A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2020-01-07","conditions":"Hereditary Angioedema","enrollment":23},{"nctId":"NCT05010876","phase":"PHASE2","title":"Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).","status":"COMPLETED","sponsor":"GCS Ramsay Santé pour l'Enseignement et la Recherche","startDate":"2021-02-04","conditions":"Covid19","enrollment":44},{"nctId":"NCT03221842","phase":"PHASE3","title":"Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients","status":"TERMINATED","sponsor":"CSL Behring","startDate":"2017-11-06","conditions":"Antibody-mediated Rejection","enrollment":63},{"nctId":"NCT04898309","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema","status":"WITHDRAWN","sponsor":"AO GENERIUM","startDate":"2021-12-01","conditions":"Hereditary Angioedema","enrollment":""},{"nctId":"NCT04414631","phase":"PHASE2","title":"Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-08-06","conditions":"Coronavirus Infections","enrollment":80},{"nctId":"NCT04489160","phase":"PHASE2","title":"Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2021-02-25","conditions":"Traumatic Brain Injury, Trauma, Head","enrollment":106},{"nctId":"NCT01426763","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase","status":"COMPLETED","sponsor":"Shire","startDate":"2011-09-12","conditions":"Hereditary Angioedema","enrollment":12},{"nctId":"NCT01095497","phase":"PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-07","conditions":"Hereditary Angioedema","enrollment":26},{"nctId":"NCT00914966","phase":"PHASE4","title":"A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE","status":"COMPLETED","sponsor":"Shire","startDate":"2009-08-31","conditions":"Hereditary Angioedema","enrollment":20},{"nctId":"NCT01147302","phase":"PHASE2","title":"A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-24","conditions":"Graft Rejection","enrollment":18},{"nctId":"NCT00289211","phase":"PHASE3","title":"C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks","status":"COMPLETED","sponsor":"Shire","startDate":"2005-03-14","conditions":"Hereditary Angioedema","enrollment":83},{"nctId":"NCT01005888","phase":"PHASE3","title":"C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks","status":"COMPLETED","sponsor":"Shire","startDate":"2005-03-14","conditions":"Hereditary Angioedema","enrollment":26},{"nctId":"NCT00097695","phase":"PHASE3","title":"Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2004-12-28","conditions":"Angioedema","enrollment":84},{"nctId":"NCT00462709","phase":"PHASE3","title":"Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks","status":"COMPLETED","sponsor":"Shire","startDate":"2006-06-27","conditions":"Hereditary Angioedema","enrollment":146},{"nctId":"NCT00438815","phase":"PHASE3","title":"Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks","status":"COMPLETED","sponsor":"Shire","startDate":"2006-09-21","conditions":"Hereditary Angioedema","enrollment":113},{"nctId":"NCT02584959","phase":"PHASE3","title":"Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2015-11-01","conditions":"Hereditary Angioedema (HAE)","enrollment":75},{"nctId":"NCT02052141","phase":"PHASE3","title":"Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2014-03-20","conditions":"Hereditary Angioedema (HAE)","enrollment":12},{"nctId":"NCT01095510","phase":"PHASE2","title":"CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12","status":"COMPLETED","sponsor":"Shire","startDate":"2010-06-02","conditions":"Hereditary Angioedema (HAE)","enrollment":9},{"nctId":"NCT01756157","phase":"PHASE2","title":"Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks","status":"COMPLETED","sponsor":"Shire","startDate":"2013-02-04","conditions":"Hereditary Angioedema (HAE)","enrollment":47},{"nctId":"NCT02663687","phase":"PHASE1","title":"Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Shire","startDate":"2016-02-19","conditions":"Hereditary Angioedema (HAE)","enrollment":48},{"nctId":"NCT00432510","phase":"PHASE1","title":"Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects","status":"COMPLETED","sponsor":"Shire","startDate":"2006-10-09","conditions":"Hereditary Angioedema","enrollment":27},{"nctId":"NCT02865720","phase":"PHASE3","title":"Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)","status":"COMPLETED","sponsor":"Shire","startDate":"2016-09-08","conditions":"Hereditary Angioedema (HAE)","enrollment":8},{"nctId":"NCT01541423","phase":"","title":"A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"Shire","startDate":"2012-05-11","conditions":"Hereditary Angioedema (HAE)","enrollment":83},{"nctId":"NCT03576469","phase":"PHASE4","title":"A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions","status":"COMPLETED","sponsor":"IMMUNOe Research Centers","startDate":"2018-06-13","conditions":"CVI - Common Variable Immunodeficiency","enrollment":20},{"nctId":"NCT01576523","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-04","conditions":"Hereditary Angioedema Types I and II","enrollment":18},{"nctId":"NCT01912456","phase":"PHASE3","title":"A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-01","conditions":"Hereditary Angioedema Types I and II","enrollment":90},{"nctId":"NCT01694381","phase":"EARLY_PHASE1","title":"Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor","status":"TERMINATED","sponsor":"TSI, LLC","startDate":"2012-09","conditions":"Acute Ischemic Stroke","enrollment":8},{"nctId":"NCT03791476","phase":"PHASE1","title":"RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function","status":"UNKNOWN","sponsor":"University of Wisconsin, Madison","startDate":"2019-06-21","conditions":"Kidney Failure","enrollment":20},{"nctId":"NCT02435732","phase":"PHASE1","title":"CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%","status":"UNKNOWN","sponsor":"University of Wisconsin, Madison","startDate":"2020-12","conditions":"Kidney Failure","enrollment":72},{"nctId":"NCT02547220","phase":"PHASE3","title":"A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant","status":"TERMINATED","sponsor":"Shire","startDate":"2016-05-20","conditions":"Acute Antibody-Mediated Rejection (AMR)","enrollment":39},{"nctId":"NCT03051698","phase":"PHASE4","title":"C1-inhibitor in Allergic ASThma Patients","status":"TERMINATED","sponsor":"T. van der Poll","startDate":"2016-11-16","conditions":"Asthma","enrollment":37},{"nctId":"NCT03664999","phase":"","title":"Serum Immunologic Markers Levels in During the Delivery","status":"COMPLETED","sponsor":"Brno University Hospital","startDate":"2018-09-08","conditions":"Immunologic Markers","enrollment":57},{"nctId":"NCT02936479","phase":"PHASE2","title":"C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2016-10","conditions":"Antibody Mediated Rejection of Kidney Transplant","enrollment":1},{"nctId":"NCT03828279","phase":"","title":"Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II","status":"UNKNOWN","sponsor":"HAE Global Registry Foundation","startDate":"2017-10-01","conditions":"Hereditary Angioedema Type I and II","enrollment":220},{"nctId":"NCT02316353","phase":"PHASE3","title":"A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-12-31","conditions":"Hereditary Angioedema Types I and II","enrollment":126},{"nctId":"NCT02869347","phase":"PHASE2","title":"Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-01","conditions":"Acute Kidney Injury","enrollment":80},{"nctId":"NCT00851409","phase":"PHASE2","title":"A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2009-06","conditions":"Genetic Disorders, Hereditary Angioedema","enrollment":25},{"nctId":"NCT02134314","phase":"PHASE1, PHASE2","title":"C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2014-09","conditions":"End Stage Renal Disease, Kidney Failure, Delayed Graft Function","enrollment":70},{"nctId":"NCT02247739","phase":"PHASE2","title":"A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2014-12","conditions":"Hereditary Angioedema","enrollment":32},{"nctId":"NCT01134510","phase":"PHASE1, PHASE2","title":"Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection","status":"COMPLETED","sponsor":"Stanley Jordan, MD","startDate":"2011-08","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT01467947","phase":"PHASE4","title":"Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-11","conditions":"Hereditary Angioedema Types I and II","enrollment":46},{"nctId":"NCT01188564","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2011-01","conditions":"Hereditary Angioedema","enrollment":75},{"nctId":"NCT00292981","phase":"PHASE3","title":"C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2005-08","conditions":"Hereditary Angioedema","enrollment":57},{"nctId":"NCT00168103","phase":"PHASE2, PHASE3","title":"Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2005-06","conditions":"Hereditary Angioedema","enrollment":126},{"nctId":"NCT01275976","phase":"PHASE3","title":"Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2012-04","conditions":"Trauma, Inflammation, Sepsis","enrollment":11},{"nctId":"NCT01766414","phase":"PHASE3","title":"In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-09","conditions":"Innate Immune Response, Endotoxemia, Inflammation","enrollment":20},{"nctId":"NCT01759602","phase":"PHASE1","title":"C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation","status":"COMPLETED","sponsor":"Michael Levy","startDate":"2013-01","conditions":"Neuromyelitis Optica","enrollment":10},{"nctId":"NCT01108848","phase":"","title":"Patient Registry Study of Berinert® in Normal Clinical Practice","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2010-04","conditions":"Includes: Hereditary Angioedema","enrollment":318},{"nctId":"NCT00261053","phase":"PHASE2","title":"Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2003-06","conditions":"Genetic Disorders","enrollment":14},{"nctId":"NCT01760343","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2013-01","conditions":"Hereditary Angioedema Types I and II","enrollment":16},{"nctId":"NCT00225147","phase":"PHASE2, PHASE3","title":"Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2005-07","conditions":"Hereditary Angioedema, Angioneurotic Edema","enrollment":77},{"nctId":"NCT00262288","phase":"PHASE2, PHASE3","title":"Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2004-04","conditions":"Genetic Disorders","enrollment":14},{"nctId":"NCT01151735","phase":"PHASE4","title":"C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation","status":"WITHDRAWN","sponsor":"Penn State University","startDate":"2010-07","conditions":"Hereditary Angioedema","enrollment":""},{"nctId":"NCT00262301","phase":"PHASE3","title":"Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema","status":"COMPLETED","sponsor":"Pharming Technologies B.V.","startDate":"2004-06","conditions":"Hereditary Angioedema, Angioneurotic Edema, Genetic Disorders","enrollment":75},{"nctId":"NCT01035593","phase":"PHASE2","title":"Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation","status":"WITHDRAWN","sponsor":"Pharming Technologies B.V.","startDate":"2010-12","conditions":"Graft Rejection, Kidney Transplantation","enrollment":""},{"nctId":"NCT00785018","phase":"NA","title":"In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-11","conditions":"Endotoxemia, Inflammation, Multi Organ Dysfunction Syndrome","enrollment":20},{"nctId":"NCT00748202","phase":"PHASE3","title":"Berinert P Study of Subcutaneous Versus Intravenous Administration","status":"COMPLETED","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2008-09","conditions":"Hereditary Angioedema","enrollment":24},{"nctId":"NCT00125541","phase":"PHASE2, PHASE3","title":"C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2006-11","conditions":"Angioedema","enrollment":6},{"nctId":"NCT00119431","phase":"PHASE2","title":"Kinetics, Efficacy and Safety of C1-Esteraseremmer-N","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2005-09","conditions":"Hereditary Angioedema Type I, Angioneurotic Edema","enrollment":12},{"nctId":"NCT00125151","phase":"PHASE3","title":"C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2006-02","conditions":"Angioedema","enrollment":15}],"_emaApprovals":[],"_faersSignals":[{"count":1655,"reaction":"HEREDITARY ANGIOEDEMA"},{"count":1368,"reaction":"OFF LABEL USE"},{"count":1037,"reaction":"DRUG INEFFECTIVE"},{"count":769,"reaction":"MATERNAL EXPOSURE DURING PREGNANCY"},{"count":751,"reaction":"PAIN"},{"count":741,"reaction":"SYSTEMIC LUPUS ERYTHEMATOSUS"},{"count":730,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":730,"reaction":"SWELLING"},{"count":721,"reaction":"TYPE 2 DIABETES MELLITUS"},{"count":720,"reaction":"PSORIATIC ARTHROPATHY"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":81,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Berinert","genericName":"Berinert","companyName":"Cedars-Sinai Medical Center","companyId":"cedars-sinai-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}